Article
The anti-ischemia agent ranolazine promotes the development of intestinal tumors in APC(Min/+) mice.
Cancer letters - 25 Jun 2004
Suckow Mark A, Gutierrez Linda S, Risatti Christina A, Wolter William R, Taylor Richard E, Pollard Morris, Navari Rudolph M, Castellino Francis J, Paoni Nicholas F
Abstract excerpt
Ranolazine was shown to improve exercise parameters in patients with chronic angina. It works by switching myocardial energy metabolism from fatty acids to glucose, thus increasing the efficiency of ATP production under hypoxic conditions. Tumors are hypoxic and may also respond to ranolazine. We found that ranolazine caused a dose-dependent increase in tumor number in APC(Min/+) mice, a model of spontaneous...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
